TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01408550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPB-01
Description: Intravenous immunoglobulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline
Study: NCT01957163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The matching placebo DPI identical in appearance to the inhaler containing active study medication.
Study: NCT01823406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp (normal blood sugar clamp) for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp (normal blood sugar clamp) for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp (normal blood sugar clamp) for 4 hours
Study: NCT02132923

Intervention type: BIOLOGICAL
Intervention: No intervention
Description: This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
Study: NCT00644930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: invasive ventilation
Description: Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist-control or synchronized intermittent mandatory ventilation (SIMV) mode.
Study: NCT00307021

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: 3-dose intramuscular injection, 2 different formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: 3-dose intramuscular injection, 2 different formulations
Study: NCT01178528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivabradine
Description: 7.5 mg bd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug:Carvedilol and Drug:Ivabradine
Description: up to 12.5/5 mg bd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 25 mg bd
Study: NCT01243437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: * For adults and children aged \> 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxyxcycline
Description: * For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer.
Study: NCT04204473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591(10mg,40mg) qd. po
Description: Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
Study: NCT01591343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depigoid® (500 DPP/ml)
Description: Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection
Study: NCT03190915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration or biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT04150263

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraocular lens (IOL) ab externo scleral suture fixation
Description: traditional IOL scleral suture fixation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modified IOL ab externo scleral suture fixation
Description: Modified IOL scleral suture fixation
Study: NCT02987452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance exercise
Description: resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
Study: NCT01282307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Determination GSD
Description: The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
Study: NCT01862471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression
Description: Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
Study: NCT01372072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
Description: Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
Study: NCT02151981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cross-over to Osimertinib
Description: Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with Osimertinib 80mg, once daily. These subjects may continue treatment with Osimertinib even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to Osimertinib.
Study: NCT02826434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-410
Description: This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: This is an intravenous infusion of a monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiltonol
Description: This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
Study: NCT02978911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative cerebral MRI and operative findings
Study: NCT01948050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial direct current stimulation (tDCS)
Study: NCT03294057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-coaching programs
Description: Tele-coaching program conducted 12 times (one time for one week), and more than 20 minutes each by a trained nurse. Coaching content specifically, 1) evaluation, 2) facing and accepting the health crisis, 3) setting up new goals, 4) making decisions and plans, and 5) practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICT programs
Description: ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICT programs
Description: ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A book about chronic disease
Description: A Take-home book about chronic disease are provided for self-education
Study: NCT01823406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp (normal blood sugar clamp) for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperglycemic clamp (elevated blood sugar to 300) for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperglycemic clamp (elevated blood sugar to 300) for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperglycemic clamp (elevated blood sugar to 300) for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperglycemic clamp (elevated blood sugar to 300) for 4 hours
Study: NCT00297349

Intervention type: DRUG
Intervention: Topiramate
Description: Individualization of the treatment should begin from 25 mg for 1 week.
Study: NCT00979459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006 DFC
Description: Each dry filled capsule contains 20 mg MK-1006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006 FCT
Description: Each film coated tablet contains 40 mg of MK-1006
Study: NCT04239222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revo-M
Description: Investigational energy storage and return prosthetic foot with using novel elastic elements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revo-M
Description: Investigational energy storage and return prosthetic foot with using novel elastic elements.
Study: NCT01595451

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
Study: NCT02131922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive Treatment
Description: Intensive Surgical Treatment of Periodontitis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dental Hygienization Treatment
Study: NCT04239222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revo-M
Description: Investigational energy storage and return prosthetic foot with using novel elastic elements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revo-M
Description: Investigational energy storage and return prosthetic foot with using novel elastic elements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taleo
Description: Commercially available carbon-fiber energy storage and return foot used as comparative foot for transfemoral amputee subjects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taleo
Description: Commercially available carbon-fiber energy storage and return foot used as comparative foot for transfemoral amputee subjects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proflex XC
Description: Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proflex XC
Description: Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects
Study: NCT01790178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
Study: NCT02987452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance exercise
Description: resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined exercise
Description: combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
Study: NCT02131922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (Intensive Treatment)
Description: Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
Study: NCT03543904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-operative physiotherapy education
Description: Pre-operative education regarding post-operative physiotherapy intervention in children with abdominal surgery which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-operative physiotherapy intervention
Description: Post-operative physiotherapy intervention which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises
Study: NCT02987452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined exercise
Description: combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
Study: NCT01790256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereve Sleep System at 30 degrees C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereve Sleep System at 14-16 degrees C
Study: NCT02099357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Daily supplementation with 3g of monohydrate creatine during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D supplementation with 25000 IU each two weeks during eight weeks
Study: NCT01548482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV
Study: NCT00989794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GelrinC
Description: Applied once during surgery
Study: NCT01428089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01010386

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Atmospheric oxygen tension
Description: Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiologic oxygen tension
Description: Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
Study: NCT01203150

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
Study: NCT04205305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional blood pressure control (labetalol, nicardipine)
Description: After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive blood pressure control (labetalol, nicardipine)
Description: After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.
Study: NCT00562276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate IUD insertion
Description: Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
Study: NCT00426855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w
Study: NCT03807869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined glaucoma surgery
Description: phacoemulsification of cataract and I-stent by-pass implantation
Study: NCT03272074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg and egg white
Description: Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg and egg white
Description: Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.
Study: NCT03982823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand-Sewn Sleeve Gastrectomy
Description: After laparoscopic sleeve gastrectomy, gastrectomy site is hand-sewn with 3/0 polypropylene suture and the specimen is removed transorally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled Sleeve Gastrectomy
Description: Laparoscopic sleeve gastrectomy is performed via 60 mm linear stapler (Endo GIATM Ultra, Covidien) .
Study: NCT02560233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contingent RT-fMRI-NF
Description: Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham RT-fMRI-NF
Description: Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
Study: NCT03006458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: toric contact lens
Study: NCT02592785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1163877
Description: Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.